The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

This report from the International Myeloma Working Group (IMWG) focuses on the multiple myeloma (MM) and its complication of lytic bone disease. Lytic bone disease is a disease that destroys the bone and can rarely be reversed. To observe lytic bone disease’s impact, “biochemical markers of bone resorption, CTX generated by matrix metalloproteinases (ICTP) and bone formation” are analyzed as bone markers. The following have increased levels in a MM patient that signify lytic bone disease and skeletal complications:

  • urinary NTX
  • serum CTX
  • werum ICTP


Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group.

Click here to view article:

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.